By the end of the webinar, participants should be able to:
Discuss current FDA approval for mAb for treatment and post-exposure prophylaxis.
Integrate mAb treatment into facility COVID response plans.
Describe different methods of mAb administration.
Apply strategies to overcome common clinical and facility-based barriers to mAb treatment.
Moderator: Sabine von Preyss-Friedman, MD, FACP, CMD
Panel: Ritu Suri, MD, CMD; Additional Panelists TBD
Sabine von Preyss-Friedman, MD, CMD, FACP, is an associate clinical professor at the University of Washington and chief medical officer of Avalon Healthcare. She first became a Certified Medical Director in 1992 and has since been enthusiastically engaged in the practice of post-acute and long-term care. She is currently a member of AMDA’s Board of Directors and serves as president of the Washington State Chapter of AMDA.